Heart Failure
Bayer funds educational initiatives on heart failure (HFmrEF/HFpEF), focusing on non-steroidal MRAs like finerenone, treatment gaps, and recent clinical evidence.
Funder: Bayer
Due Dates: Rolling (monthly review)
Funding Amounts: Amount varies by project; detailed budget required in application; typical duration is for the proposed educational activity.
Summary: Supports educational initiatives on heart failure (HFmrEF/HFpEF) with emphasis on non-steroidal MRAs, treatment gaps, and recent clinical data.
Key Information: Proposals must comply with ACCME or equivalent standards and include provider accreditation documentation.
Description
This grant from Bayer funds medical educational initiatives focused on heart failure, specifically for patients with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF, LVEF ≥40%). The program aims to address disease burden, pathophysiology, co-morbid conditions, current standards of care, and gaps in treatment. A particular emphasis is placed on the unique properties and efficacy of non-steroidal mineralocorticoid receptor antagonists (MRAs) such as finerenone, referencing recent clinical trials like FINEARTS-HF and FINEHEART. Supported activities may include enduring educational materials, downloadable resources, live virtual events, podcasts, and social media outreach.
